Molecular Diagnostics for Infectious Disease 2019 - 2023: Markets, Strategies, Trends, Volume and Price Forecasts by Pathogen and Country with Multiplex and Point of Care Market Analysis and Executive Guides

Updated November 7, 2018

Table of Contents

Multiplex testing threatens existing infectious disease practice.  The microbiology lab may disappear….

The Molecular Diagnostics – Infectious Disease sector of the clinical diagnostics industry is poised for record growth.  A market that just keeps on growing.  In spite of the steady decline of disease prevalence, the diagnostic sector keeps growing.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics.  A range of dynamic trends are pushing market growth and company valuations, such as:

• changing demographics
• emerging economies and global prosperity
• biotechnology advances in genetics
• pathogen evolution
• climate change
• globalization
• the rise of rapid testing

Exciting technical developments, especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing.    Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 15 countries and 4 regions.  A detailed breakout for any country is available to purchasers of the report.

Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options however your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance and additional specific data is provided without additional charges. 

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.   

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional.  He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping."  He has worked in laboratory testing and management for over 20 years.  Mr. Powell’s education includes:

• B.Sc. (Chemistry) University of BC
• M.B.A. (Finance and Policy) University of BC
• Market Research Seminar - Burke Institute
• Finance for Senior Executives - Harvard Business School